KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Biolife Solutions (BLFS) over the last 16 years, with Q3 2025 value amounting to $29.5 million.

  • Biolife Solutions' Cash & Equivalents rose 2295.53% to $29.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year increase of 2295.53%. This contributed to the annual value of $95.4 million for FY2024, which is 24193.43% up from last year.
  • According to the latest figures from Q3 2025, Biolife Solutions' Cash & Equivalents is $29.5 million, which was up 2295.53% from $31.9 million recorded in Q2 2025.
  • Biolife Solutions' 5-year Cash & Equivalents high stood at $95.4 million for Q4 2024, and its period low was $19.1 million during Q1 2023.
  • Its 5-year average for Cash & Equivalents is $43.5 million, with a median of $29.5 million in 2025.
  • As far as peak fluctuations go, Biolife Solutions' Cash & Equivalents skyrocketed by 129081.25% in 2021, and later crashed by 7217.01% in 2022.
  • Biolife Solutions' Cash & Equivalents (Quarter) stood at $69.9 million in 2021, then plummeted by 72.17% to $19.4 million in 2022, then soared by 43.48% to $27.9 million in 2023, then soared by 241.93% to $95.4 million in 2024, then tumbled by 69.09% to $29.5 million in 2025.
  • Its Cash & Equivalents was $29.5 million in Q3 2025, compared to $31.9 million in Q2 2025 and $66.9 million in Q1 2025.